Has the impact of the COVID-19 pandemic on uptake andusage of indwelling pleural catheters reduced its cost-effectiveness?

During the COVID pandemic, the British Thoracic Society recommended first-line indwelling pleural catheter (IPC)insertion or therapeutic aspiration for malignant pleural effusion (MPE) instead of admission for chest drain and talcpleurodesis to minimise hospital visits. This study aimed to review the uptake and usage of IPCs during and followingthe pandemic and its potential cost-effectiveness.Retrospective data analysis of IPCs between 2020-2021 was performed. Data collection included patient sex, age,WHO performance status (PS), indication and duration of IPC.187 IPCs were inserted;91% for MPE. 75% elected for IPC as first-line. 57% patients were PS 0-1 and 77% werePS 0-2. In 2020, 30% patients were self-draining compared to 12% in 2021. Mean duration IPC in-situ was 87 days(median 68 days). The pandemic saw increased use of first-line IPCs (75% 2020 vs 52% 2019) particularly in patients with good PS. This reduced initial hospitalisation (4.08 bed days) with an estimated cost saving of 1200 (300/day) per patient. Self-drainage rates also increased from 13% (2019) to 30% (2020) but have returned to pre-pandemic levels of selfdrainage at 12% in 2021 with need for district nurse visits for up to 3 months. Current practice of widespread first-line IPC use in the COVID endemic era may not be cost-effective and needs to be reviewed alongside the pre-existing evidence base.

Has COVID-19 affected complication rate ofIPC placements?

The COVID pandemic increased uptake of indwelling pleural catheters (IPC) as first-line management of malignant and non-malignant pleural effusions. This study reviewed the complication rate in view of this and its associated impact. Retrospective data analysis of IPCs between 2020-2021 was performed. Data collection included patient demographics, indication, treatment, and complication rate. 187 IPCs were inserted in 180 patients. Pneumothorax rate was low (1%). Common complications were incomplete drainage at point of IPC removal, IPC-related infection, and chronic pain. Despite incomplete drainage in 54 (29%) patients, only 8 required further procedures (1 IPC, 7 therapeutic aspirations). 80 patients received chemotherapy or immunotherapy. 11% developed IPC-related infection: 7% pleural infection and 4% cellulitis. 100 patients did not receive immunosuppressive treatment: 2% had pleural infection. Pleural infection occurred 8 weeks post-insertion (median 63 days) requiring 19 bed days per patient and 1 IPC removal. 2 IPCs were removed due to intractable chronic pain. Overall, complications associated with IPC in our practice were lower than recently published data. IPC-related infection is a problem;however, our study was underpowered, and the effect of immunosuppressive treatment could not be analysed. Despite this, most patients required conservative treatment only and did not require IPC removal, allowing ongoing usage of the IPC.

An extensive study on the COVID-19 pandemic, an emerging global crisis: Risks, transmission, impacts and mitigation.

A number of unexplained cases of pneumonia have been recorded since November 2019 in China. It is officially named the new corona virus (2019-nCov) by the World Health Organization on 12 January 2020. WHO officially named it COVID-19 on 11 February. COVID-19 is a highly transmitted and pathogenic viral infection that has been developed and spread across the world in Wuhan, China, caused by extreme acute respiratory syndrome corona-virus 2 (SARS-CoV-2). Genomic analysis showed that bats may also be a primary reservoir of SARS-CoV-2 phylogenetically associated with severe acute respiratory syndrome-like viruses (SARS). However, the rapid human to human transition has been generally reported. Intermediate source of origin and human transition is unknown. Clinically approved COVID-19 antiviral medication or vaccine is not available. In clinical trials, however, few broad-based COVID-19 antiviral medicinal drugs were tested, resulting in clinical recovery. This analysis summarizes the pathogenicity of COVID-19 and aims to raise awareness of COVID-19 among the population and to continually boost the detection, monitoring, diagnosis and care level. Over 50 COVID-19 scientific publications were included in this systematic analysis. We found that fever (87.0%), cough (65.9%) and malaise/tiredness (35%) were the most common symptoms of COvida-19. However, COVID-19 clinical signs and symptoms were not necessarily obvious. The transmission of COVID-19 in comparison to SARS was more specific. The rate of death of COVID-19 was 2,7% and the pathological characteristics of COVID-19 are very similar to ARDS. There are also discussions on the latest epidemiological changes, clinical manifestations, auxiliary examination and COVID-19 pathological characteristics.